news
-
21 June 2023Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)
Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces additional data on safety, quality of life and survival from POSEIDON, its North American pivotal study of alfapump for the treatment of patients with recurrent or refractory ascites due to liver cirrhosis. These data will be presented during a poster session today and have been selected for an oral poster presentation on June 23rd from 12:45 to 12:55 CEST at the EASL Congress in Vienna, Austria.
Professor Florence Wong, University of Toronto, Hepatologist at Toronto General Hospital, Ontario, Canada and Principal Investigator for the POSEIDON study, commented: “Recurrent or refractory ascites has a negative impact on patients’ lives requiring management with regular paracentesis. The results from the POSEIDON study have shown that the alfapump is very effective at controlling this, virtually eliminating the need for large volume paracentesis and significantly improving patients’ quality of life at six months post-implantation. While patients implanted with the alfapump need to be closely monitored for the development of acute kidney injury or infection, in the POSEIDON study these events readily resolved with the standard of care.”
Ian Crosbie, Chief Executive Officer at Sequana Medical, added: “We are excited about this further POSEIDON data as we believe it continues to support alfapump as a breakthrough for recurrent or refractory liver ascites patients. Together with the positive primary endpoint data reported previously, these results further support the clinical benefits of the alfapump and show a survival rate that compares favorably to literature. With more than 75,000 people in North America suffering from recurrent or refractory liver ascites by 2025, and growing by 6-7% a year due to NASH, modern and effective solutions like alfapump are urgently needed.”
Related
Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards
Sequana Medical successfully raises EUR 15.78 million in an Equity Placement
Sequana Medical announces 2022 Full Year Results and 2023 Outlook
Sequana Medical announces grant of additional DSR® patent in United States
Sequana Medical announces H1 2022 results and provides business update
Alexandra Clyde appointed to Sequana Medical Board of Directors
Sequana Medical secures EUR 10 million loan facility with Kreos Capital
Sequana Medical announces new Share Capital Amount and New Number of Shares
Sequana Medical receives certification under MDR, the new European Medical Device Regulation
Sequana Medical announces H1 2021 results and provides business update
Sequana Medical appoints Jackie Fielding, former Medtronic VP, to its Board of Directors
Sequana Medical announces first patient enrolled in SAHARA DESERT
Sequana Medical announces 2020 Full Year Results and 2021 Outlook
Sequana Medical announces granting of key alfapump DSR® patents in U.S. and Europe
Sequana Medical announces H1 2020 results and provides business update
Sequana Medical announces €7.3 million debt financing and provides clinical update
Sequana Medical announces 2019 Full Year Results and 2020 Outlook
Sequana Medical announces new share capital amount and new number of shares
Sequana Medical announces 2019 Half Year Results and Year-to-date Business Update
Sequana Medical appoints leading experts as Heart Failure Scientific Advisors
Sequana Medical to host webcast on 27 May 2019
Sequana Medical announces 2018 Full Year Results and 2019 Outlook
Sequana Medical raises €27.5 million in successful Initial Public Offering
Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study
Sequana Medical Announces Results of the MOSAIC trial data presented at 2017 AASLD
Sequana Medical Announces Sudden Passing of Founder, President & CEO
Ian Crosbie Joins Sequana Medical as Chief Financial Officer
Sequana Medical has been selected as a finalist for the 2012 MEDTEC EMDT Innovation Awards
Sequana Medical receives CE Mark Approval for the ALFApumpTM System and adds key executive to team
NovaShunt announces the launch of its new corporate identity: Sequana Medical